Home > News > Trending news > L2Mtech GmbH Receives CE Mark Approval on 6(SIX) products for Cardiovascular and Endovascular Applications

Health Technology

L2Mtech GmbH Receives CE Mark Approval on 6(SIX) products for Cardiovascular and Endovascular Applications

L2Mtech | February 17, 2021

  • CE Mark Approval for LimusTrack™, Sirolimus Eluting Coronary Stent System for Cardiovascular Applications.
  • CE Mark Approval for LomiFlow™, Paclitaxel Drug Eluting Balloon for Cardiovascular Applications
  • CE Mark Approval for PearlFlow™, Paclitaxel Drug Elutin Balloon for Endovascular Applications
  • CE Mark Approval for PearlFlow NS™, Self Expandable Nitinol Stent System for Endovascular Applications
  • CE Mark Approval for FlexiTrack 018™, Peripheral Balloon Catheter for Endovascular Applications
  • CE Mark Approval for FlexiTrack 035™, Peripheral Balloon Catheter for Endovascular Applications

Bonn, Germany – L2Mtech GmbH has announced the award of its first CE Mark approval on Six (6) products:

  1. LimusTrack™ : Sirolimus Coated Cobalt Chromium Stent with biodegradable polymer for the treatment of coronary artery disease, de novo lesions, restenosis lesions.
  2. LomiFlow™ : Paclitaxel Coated balloon catheter for the treatment of coronary artery disease, small vessels, dilatation of de novo lesions, in-stent restenosis (ISR) cases.
  3. PearlFlow™ : Paclitaxel Coated balloon catheter for the treatment of peripheral arterial disease, PTA, dilatation of stenotic segments or lesions in peripheral arteries.
  4. PearlFlow NS™ : Self-Expanding Nitinol Stent System for the treatment of peripheral arterial disease, de novo lesions, lesions in femoropopliteal arteries.
  5. FlexiTrack 018™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in femoral, popliteal, tibial arteries.
  6. FlexiTrack 035™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in the SFA, femoral arteries.

L2Mtech GmbH Founder and CEO Lalit Mamtani said ‘‘We are very excited to have been awarded our first CE Mark on six products, CE Mark approval represents a key milestone for L2Mtech GmbH and is a testament to the efficacy and safety of our innovative technology products for Cardiovascular and Endovascular applications.“

We now prepare to commercially launch the products in all markets where the CE Mark is recognized. With introduction of our innovative technology products in markets, we will be able to expand treatment options for the benefit of many millions of patients with coronary and peripheral artery disease around the world.

About L2Mtech
Founded in 2017, L2Mtech GmbH is a privately-owned multinational medical device company headquartered at Bonn, Germany. L2Mtech specializes in design, development, manufacture and commercialization of medical devices that are used by healthcare establishments globally. L2MTech will provide interventional physicians with innovative vascular devices including Drug Eluting Balloon manufactured in Europe.Our Core mission is to build a product portfolio focused on minimally invasive treatment for patients with cardiovascular,endovascular and vascular artery disease. For further information, please visit : L2MTech.de

Media Contact:
L2Mtech GmbH
admin@L2Mtech.de
+49 228 94730761

Spotlight

Prevantics Device Swab Instructions For Use (IFU) Video - Blood Cultural Bottle Tops

This instructions for use video contains step-by-step directions on how to properly disinfect blood cultural bottle tops with Prevantics® Device Swab.


Other News
Health Technology

CareView Launches Software 5.10 for Improved Virtual Care Solutions

CareView Communications | September 13, 2023

CareView Communications, Inc., a prominent provider of integrated virtual care solutions for the healthcare sector, has announced the introduction of its most recent milestone in patient care technology through the unveiling of Software Version 5.10. This release incorporates many cutting-edge features and improvements meticulously crafted to empower healthcare professionals and enhance patient results. Software Release 5.10 introduces a range of significant enhancements, beginning with the seamless integration of CareView with Get Well, a leading patient engagement platform. This integration facilitates bidirectional video communication, ultimately elevating patient engagement, education, and overall satisfaction. Additionally, a new Universal Dashboard has been introduced. This internal tool plays a crucial role in optimizing solutions. It leverages hospital utilization data along with machine learning algorithms to provide predictive analytics and enables in-depth analyses, significantly enhancing the overall offerings. Derek del Carpio, CareView's VP of Product Development, stated, At CareView, we continuously strive to provide innovative solutions that redefine patient care. Software Release 5.10 is a testament to our commitment to advancing virtual care technology and enhancing the well-being of patients. [Source: Business Wire] Further, substantial improvements have been applied to the Virtual Sitting feature, empowering CareView Controllers to manipulate associated views through EquipmentView and introducing Night Mode in SitterView to reduce eye strain, thus enhancing both patient monitoring flexibility and safety. Virtual Nursing has also undergone notable refinements, enabling the virtual Registered Nurse to mute participants during TeleCareView encounters, facilitating participants' easy transition between viewing fellow participants and shared screens, and granting healthcare providers the capability to blur backgrounds in TeleCareView, thereby fostering a more professional and focused virtual interaction environment. CareView maintains a steadfast commitment to fostering collaboration with healthcare providers to elevate patient safety, optimize clinical processes, and enhance overall patient care quality. Introducing this latest software release further underscores CareView's unwavering dedication to providing hospital teams with innovative virtual care solutions to meet their evolving needs. About CareView Communications CareView, leveraging predictive technology and purpose-built hardware, has forged partnerships with more than 200 hospitals to tackle pressing staffing issues and elevate patient safety through its platform. The company collaborates closely with its hospital partners to deliver tailored virtual care strategies that improve patient outcomes and foster a sustainable healthcare ecosystem.

Read More

Healthcare Analytics

FDA Grants De Novo for Xenex's LightStrike+ UV Robot in Healthcare

Xenex | September 11, 2023

United States Food and Drug Administration (USFDA) has issued a De Novo authorization to Xenex Disinfection Services, Inc. (Xenex) for its LightStrikeTM+ device, an advanced high-intensity, broad-spectrum ultraviolet (UV) light robot. The LightStrike+ devices are designed for microbial reduction on non-critical medical device surfaces in healthcare environments, following manual cleaning and disinfection practices. They are authorized for use in various healthcare settings, including unoccupied operating rooms and hospital rooms. These devices have an impressive track record, with over 1,200 healthcare facilities worldwide employing LightStrike robots for over 37 million cycles. The new LightStrike+ device, capable of microbial reduction in as little as 2 minutes, represents the culmination of over a decade of knowledge accumulation from healthcare facilities' best practices, supported by 45 peer-reviewed studies demonstrating its safety and effectiveness, a portfolio of 193 patents, and unparalleled technical and epidemiological expertise. Dr. Mark 'Tuck' Stibich, Xenex's Founder and Chief Scientific Officer, emphasized the long-standing collaboration with healthcare partners spanning more than a decade to enhance patient safety and public health. As an infectious diseases epidemiologist, Dr. Stibich expressed concern about antibiotic resistance within hospital environments and the potential for FDA authorization to facilitate the broader adoption of the LightStrike+ tool in combating pathogens. Perilous pathogens persist on surfaces within healthcare facilities, notwithstanding diligent manual cleaning endeavors. The LightStrike+ robot employs a xenon lamp to generate high-intensity pulsed UV light, which effectively diminishes the presence of these pathogens on surfaces and plays a pivotal role in interrupting the transmission chain from one patient or healthcare worker to another. Xenex's FDA authorization is substantiated by comprehensive testing conducted on more than 10,000 samples of vegetative bacteria and Clostridiodes difficile (C. diff) spores. This authorization establishes a novel medical device product classification, with the LightStrike+ robot being its inaugural and sole product. It is a landmark in the FDA's regulatory framework for UV robots designed to diminish pathogens on non-porous, frequently touched surfaces within healthcare settings. Furthermore, Xenex's Chief Executive Officer, Morris Miller, acknowledged the challenges hospitals face when evaluating UV technologies, citing the prevalence of unverified and exaggerated claims by some manufacturers. He underscored the significance of FDA authorization in instilling confidence among hospital decision-makers, assuring them of the accuracy and validation of Xenex's claims regarding the LightStrike+ device. Numerous world-renowned hospitals, such as HonorHealth, Mayo Clinic, MD Anderson Cancer Center, Ochsner Health System, Stanford Health Care, and Texas Health Resources, have integrated LightStrike robots into their comprehensive disinfection strategies. About Xenex Xenex is a global leader in pioneering strategies and solutions grounded in UV technology. Its fundamental mission revolves around enabling its partners to safeguard lives and reduce human suffering by eliminating the dangerous microorganisms that cause infections. The company benefits from substantial support from renowned investors, including EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures, and RK Ventures.

Read More

Health Technology, Digital Healthcare

Aspect Imaging to bring Improvements in NICUs for Vizient

Aspect Imaging | September 25, 2023

Aspect Imaging, a global leader in MRI systems for neonatal patients, has been awarded an Innovative Technology contract by Vizient, the nation's largest provider -driven healthcare performance improvement company. This contract recognizes the unique qualities of Aspect Imaging's Embrace Point of Care Neonatal MRI System and its potential to bring improvements to the healthcare industry. The Embrace Point of Care Neonatal MRI System is designed specifically for the imaging needs of prematureand newborn infants, making it a critical tool in neonatal intensive care units (NICUs). The Embrace is the world's first FDA-cleared and CE-approved MRI system for neonatal patients. It is designed to be placed directly within NICUs, overcoming the size and risk limitations associated with adult MRI scanners. The system includes features such as a temperature-controlled patient bed and a Whisper Quiet sound profile to meet the specific care needs of neonatal patients. This technology enables safer and more accessible MRI imaging for fragile neonatal patients and provides critical information to the clinical care team. Chief Commercial Officer at Aspect Imaging, Wendy Slatery, stated, It is an honor to have the Embrace recognized by the clinical experts at Vizient, as an Innovative Technology, and an exciting opportunity to bring valuable solutions to Vizient customers. We are looking forward to working with Vizient members seeking to expand and elevate neurocritical care of the smallest patients while reducing patient risks and staff time associated with transporting newborns to a traditional MRI. The Embrace MRI gives the neonatal medical team access to information from the life’s first hours and throughout the patient’s time in the NICU, on which critical care decisions will be based. [Source: Business Wire] Vizient's provider customer-led councils recommended the Embrace system for an Innovative Technology contract after evaluating its potential to enhance clinical care, patient safety, and healthcare worker safety, or improve business operations in healthcare organizations. The recognition and award of this contract highlight the potential of the Embrace Point of Care Neonatal MRI System to improve neurocritical care for the smallest patients while reducing risks associated with transporting newborns to traditional MRI facilities. About Aspect Imaging Aspect Imaging, a pioneering force in the field, stands as the global frontrunner in crafting and advancing compact MR imaging systems tailored for both research and clinical use. Their groundbreaking technology centers on compact, high-performance permanent magnets, introducing transformative MRI solutions to tackle unmet requirements in research and medical contexts. These innovations ensure the delivery of the finest quality images, whether at the benchtop or in point-of-care scenarios.

Read More

Digital Healthcare

ClosedLoop Introduces Data Science Products for Value-Based Healthcare

ClosedLoop | September 20, 2023

ClosedLoop, a prominent healthcare data science platform, has formally introduced two novel data science solutions. These solutions, namely, ACO-Predict and Evaluate, are crafted to assist healthcare organizations in the comprehensive analysis, assessment, ongoing surveillance, and enhancement of their programs, with the objectives of minimizing adverse events, enhancing health outcomes, and curtailing expenditures. ClosedLoop's offering, ACO-Predict, marks the healthcare sector's inaugural no-cost AI-powered solution for population health risk stratification. It harnesses the same algorithms that propelled ClosedLoop to garner fame in the 2021 CMS AI Challenge and earned the Best in KLAS Healthcare AI ranking for 2022 and 2023. When integrated with the updated Beneficiary Claims Data API data feeds from the Centers for Medicare and Medicaid Services, the product furnishes Medicare Accountable Care Organizations with a turnkey risk stratification tool for Complex Care Management programs, all free of charge. Meanwhile, the company's second product, ClosedLoop Evaluate, is a SaaS solution designed to evaluate and continuously monitor the efficacy of intricate population health initiatives over extended durations. Quantifying the impact and ROI of Population Health programs has presented significant challenges. Organizations often need to resort to imprecise pre- and post-assessments or enlist costly consulting firms for one-off outcome research studies to understand the actual effects of their programs. ClosedLoop’s solutions aim to improve healthcare organizations' outcomes and offer essential patient support. Jennifer Zbell, VP of Clinical Analytics at Healthfirst, stated, ClosedLoop provided the quantitative evidence we needed to increase investment in successful programs." She added, "Evaluate gives us the confidence to examine our programs across the board so we can better see what's working, when it's working, and who it's working for. [Source – Business Wire] ClosedLoop Evaluate represents a pioneering industry solution that not only supplants these studies with software-driven evaluations but also facilitates the ongoing assessment of program impact amid evolving programs and populations. Andrew Eye, Co-Founder and CEO of ClosedLoop concluded that success in value-based care hinges on two key aspects: accurate prediction and effective intervention. ACO-Predict delivers AI-powered prediction capabilities to all medicare patients nationwide at no cost, ensuring access to necessary assistance regardless of location or ACO resources. About ClosedLoop ClosedLoop is a dedicated data science platform tailored to the healthcare sector, simplifying the integration of AI technology to enhance outcomes and curtail expenses. Uniquely designed for the healthcare domain, the company merges an intuitive, all-encompassing ML platform with an extensive repository of healthcare-specific functionalities and model templates. Customers leverage ClosedLoop's Explainable AI capabilities to facilitate clinical excellence, streamline operational processes, navigate value-based contracts, and bolster revenue generation in the healthcare industry.

Read More

Health Technology

CareView Launches Software 5.10 for Improved Virtual Care Solutions

CareView Communications | September 13, 2023

CareView Communications, Inc., a prominent provider of integrated virtual care solutions for the healthcare sector, has announced the introduction of its most recent milestone in patient care technology through the unveiling of Software Version 5.10. This release incorporates many cutting-edge features and improvements meticulously crafted to empower healthcare professionals and enhance patient results. Software Release 5.10 introduces a range of significant enhancements, beginning with the seamless integration of CareView with Get Well, a leading patient engagement platform. This integration facilitates bidirectional video communication, ultimately elevating patient engagement, education, and overall satisfaction. Additionally, a new Universal Dashboard has been introduced. This internal tool plays a crucial role in optimizing solutions. It leverages hospital utilization data along with machine learning algorithms to provide predictive analytics and enables in-depth analyses, significantly enhancing the overall offerings. Derek del Carpio, CareView's VP of Product Development, stated, At CareView, we continuously strive to provide innovative solutions that redefine patient care. Software Release 5.10 is a testament to our commitment to advancing virtual care technology and enhancing the well-being of patients. [Source: Business Wire] Further, substantial improvements have been applied to the Virtual Sitting feature, empowering CareView Controllers to manipulate associated views through EquipmentView and introducing Night Mode in SitterView to reduce eye strain, thus enhancing both patient monitoring flexibility and safety. Virtual Nursing has also undergone notable refinements, enabling the virtual Registered Nurse to mute participants during TeleCareView encounters, facilitating participants' easy transition between viewing fellow participants and shared screens, and granting healthcare providers the capability to blur backgrounds in TeleCareView, thereby fostering a more professional and focused virtual interaction environment. CareView maintains a steadfast commitment to fostering collaboration with healthcare providers to elevate patient safety, optimize clinical processes, and enhance overall patient care quality. Introducing this latest software release further underscores CareView's unwavering dedication to providing hospital teams with innovative virtual care solutions to meet their evolving needs. About CareView Communications CareView, leveraging predictive technology and purpose-built hardware, has forged partnerships with more than 200 hospitals to tackle pressing staffing issues and elevate patient safety through its platform. The company collaborates closely with its hospital partners to deliver tailored virtual care strategies that improve patient outcomes and foster a sustainable healthcare ecosystem.

Read More

Healthcare Analytics

FDA Grants De Novo for Xenex's LightStrike+ UV Robot in Healthcare

Xenex | September 11, 2023

United States Food and Drug Administration (USFDA) has issued a De Novo authorization to Xenex Disinfection Services, Inc. (Xenex) for its LightStrikeTM+ device, an advanced high-intensity, broad-spectrum ultraviolet (UV) light robot. The LightStrike+ devices are designed for microbial reduction on non-critical medical device surfaces in healthcare environments, following manual cleaning and disinfection practices. They are authorized for use in various healthcare settings, including unoccupied operating rooms and hospital rooms. These devices have an impressive track record, with over 1,200 healthcare facilities worldwide employing LightStrike robots for over 37 million cycles. The new LightStrike+ device, capable of microbial reduction in as little as 2 minutes, represents the culmination of over a decade of knowledge accumulation from healthcare facilities' best practices, supported by 45 peer-reviewed studies demonstrating its safety and effectiveness, a portfolio of 193 patents, and unparalleled technical and epidemiological expertise. Dr. Mark 'Tuck' Stibich, Xenex's Founder and Chief Scientific Officer, emphasized the long-standing collaboration with healthcare partners spanning more than a decade to enhance patient safety and public health. As an infectious diseases epidemiologist, Dr. Stibich expressed concern about antibiotic resistance within hospital environments and the potential for FDA authorization to facilitate the broader adoption of the LightStrike+ tool in combating pathogens. Perilous pathogens persist on surfaces within healthcare facilities, notwithstanding diligent manual cleaning endeavors. The LightStrike+ robot employs a xenon lamp to generate high-intensity pulsed UV light, which effectively diminishes the presence of these pathogens on surfaces and plays a pivotal role in interrupting the transmission chain from one patient or healthcare worker to another. Xenex's FDA authorization is substantiated by comprehensive testing conducted on more than 10,000 samples of vegetative bacteria and Clostridiodes difficile (C. diff) spores. This authorization establishes a novel medical device product classification, with the LightStrike+ robot being its inaugural and sole product. It is a landmark in the FDA's regulatory framework for UV robots designed to diminish pathogens on non-porous, frequently touched surfaces within healthcare settings. Furthermore, Xenex's Chief Executive Officer, Morris Miller, acknowledged the challenges hospitals face when evaluating UV technologies, citing the prevalence of unverified and exaggerated claims by some manufacturers. He underscored the significance of FDA authorization in instilling confidence among hospital decision-makers, assuring them of the accuracy and validation of Xenex's claims regarding the LightStrike+ device. Numerous world-renowned hospitals, such as HonorHealth, Mayo Clinic, MD Anderson Cancer Center, Ochsner Health System, Stanford Health Care, and Texas Health Resources, have integrated LightStrike robots into their comprehensive disinfection strategies. About Xenex Xenex is a global leader in pioneering strategies and solutions grounded in UV technology. Its fundamental mission revolves around enabling its partners to safeguard lives and reduce human suffering by eliminating the dangerous microorganisms that cause infections. The company benefits from substantial support from renowned investors, including EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures, and RK Ventures.

Read More

Health Technology, Digital Healthcare

Aspect Imaging to bring Improvements in NICUs for Vizient

Aspect Imaging | September 25, 2023

Aspect Imaging, a global leader in MRI systems for neonatal patients, has been awarded an Innovative Technology contract by Vizient, the nation's largest provider -driven healthcare performance improvement company. This contract recognizes the unique qualities of Aspect Imaging's Embrace Point of Care Neonatal MRI System and its potential to bring improvements to the healthcare industry. The Embrace Point of Care Neonatal MRI System is designed specifically for the imaging needs of prematureand newborn infants, making it a critical tool in neonatal intensive care units (NICUs). The Embrace is the world's first FDA-cleared and CE-approved MRI system for neonatal patients. It is designed to be placed directly within NICUs, overcoming the size and risk limitations associated with adult MRI scanners. The system includes features such as a temperature-controlled patient bed and a Whisper Quiet sound profile to meet the specific care needs of neonatal patients. This technology enables safer and more accessible MRI imaging for fragile neonatal patients and provides critical information to the clinical care team. Chief Commercial Officer at Aspect Imaging, Wendy Slatery, stated, It is an honor to have the Embrace recognized by the clinical experts at Vizient, as an Innovative Technology, and an exciting opportunity to bring valuable solutions to Vizient customers. We are looking forward to working with Vizient members seeking to expand and elevate neurocritical care of the smallest patients while reducing patient risks and staff time associated with transporting newborns to a traditional MRI. The Embrace MRI gives the neonatal medical team access to information from the life’s first hours and throughout the patient’s time in the NICU, on which critical care decisions will be based. [Source: Business Wire] Vizient's provider customer-led councils recommended the Embrace system for an Innovative Technology contract after evaluating its potential to enhance clinical care, patient safety, and healthcare worker safety, or improve business operations in healthcare organizations. The recognition and award of this contract highlight the potential of the Embrace Point of Care Neonatal MRI System to improve neurocritical care for the smallest patients while reducing risks associated with transporting newborns to traditional MRI facilities. About Aspect Imaging Aspect Imaging, a pioneering force in the field, stands as the global frontrunner in crafting and advancing compact MR imaging systems tailored for both research and clinical use. Their groundbreaking technology centers on compact, high-performance permanent magnets, introducing transformative MRI solutions to tackle unmet requirements in research and medical contexts. These innovations ensure the delivery of the finest quality images, whether at the benchtop or in point-of-care scenarios.

Read More

Digital Healthcare

ClosedLoop Introduces Data Science Products for Value-Based Healthcare

ClosedLoop | September 20, 2023

ClosedLoop, a prominent healthcare data science platform, has formally introduced two novel data science solutions. These solutions, namely, ACO-Predict and Evaluate, are crafted to assist healthcare organizations in the comprehensive analysis, assessment, ongoing surveillance, and enhancement of their programs, with the objectives of minimizing adverse events, enhancing health outcomes, and curtailing expenditures. ClosedLoop's offering, ACO-Predict, marks the healthcare sector's inaugural no-cost AI-powered solution for population health risk stratification. It harnesses the same algorithms that propelled ClosedLoop to garner fame in the 2021 CMS AI Challenge and earned the Best in KLAS Healthcare AI ranking for 2022 and 2023. When integrated with the updated Beneficiary Claims Data API data feeds from the Centers for Medicare and Medicaid Services, the product furnishes Medicare Accountable Care Organizations with a turnkey risk stratification tool for Complex Care Management programs, all free of charge. Meanwhile, the company's second product, ClosedLoop Evaluate, is a SaaS solution designed to evaluate and continuously monitor the efficacy of intricate population health initiatives over extended durations. Quantifying the impact and ROI of Population Health programs has presented significant challenges. Organizations often need to resort to imprecise pre- and post-assessments or enlist costly consulting firms for one-off outcome research studies to understand the actual effects of their programs. ClosedLoop’s solutions aim to improve healthcare organizations' outcomes and offer essential patient support. Jennifer Zbell, VP of Clinical Analytics at Healthfirst, stated, ClosedLoop provided the quantitative evidence we needed to increase investment in successful programs." She added, "Evaluate gives us the confidence to examine our programs across the board so we can better see what's working, when it's working, and who it's working for. [Source – Business Wire] ClosedLoop Evaluate represents a pioneering industry solution that not only supplants these studies with software-driven evaluations but also facilitates the ongoing assessment of program impact amid evolving programs and populations. Andrew Eye, Co-Founder and CEO of ClosedLoop concluded that success in value-based care hinges on two key aspects: accurate prediction and effective intervention. ACO-Predict delivers AI-powered prediction capabilities to all medicare patients nationwide at no cost, ensuring access to necessary assistance regardless of location or ACO resources. About ClosedLoop ClosedLoop is a dedicated data science platform tailored to the healthcare sector, simplifying the integration of AI technology to enhance outcomes and curtail expenses. Uniquely designed for the healthcare domain, the company merges an intuitive, all-encompassing ML platform with an extensive repository of healthcare-specific functionalities and model templates. Customers leverage ClosedLoop's Explainable AI capabilities to facilitate clinical excellence, streamline operational processes, navigate value-based contracts, and bolster revenue generation in the healthcare industry.

Read More

More Trending news

Spotlight

Prevantics Device Swab Instructions For Use (IFU) Video - Blood Cultural Bottle Tops

This instructions for use video contains step-by-step directions on how to properly disinfect blood cultural bottle tops with Prevantics® Device Swab.

Resources

Everything You Need to Know About Healthcare Technology Platforms How a 360-degree view of your business can reduce costs and solve the pain points y

Whitepaper

Porter Research for Healthcare and Life Sciences

Whitepaper

2023 State of Cybersecurityfor Medical Devices andHealthcare Systems

Whitepaper

Everything You Need to Know About Healthcare Technology Platforms How a 360-degree view of your business can reduce costs and solve the pain points y

Whitepaper

Porter Research for Healthcare and Life Sciences

Whitepaper

2023 State of Cybersecurityfor Medical Devices andHealthcare Systems

Whitepaper